Europe Vaccines Market Outlook, 2028

Vaccines designed to prevent infectious diseases are one of the most cost-effective health care interventions. The World Health Organization estimates that existing vaccines prevent approximately 2-3 million deaths per year. Vaccines provide direct benefits by preventing infections, hospitalizations, medical complications and their related treatment costs and also indirect benefits such as minimizing the impact of vaccine-preventable diseases on family or improving labor productivity. Today, close to 30 diseases are preventable by vaccination Vaccines Europe (VE), a specialized group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), represents 14 vaccine companies operating in Europe. Today, 75% of VE member’s production is taking place in EU, which represents 1.7 billion of vaccine doses annually used to immunize populations worldwide. VE member companies are dedicated to improving public health by making immunization feasible and are committed to ensure availability of safe, efficacious and high-quality vaccines. The European Commission has secured deals with Pfizer and several European drug makers to reserve capacity to make up to 325 million vaccines per year in case of a future global health emergency. Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities. These include the European Medicines Agency (EMA) and other regulators in the EU/EEA countries.

According to the research report, “Europe Vaccine Market Outlook, 2028” the market is anticipated to add more than USD 7 Billion from 2023 to 2028. A number of variables that combined improved public health outcomes across Europe in recent years have led to a noticeable rise in vaccine uptake in that continent. The increased public knowledge of the value of vaccines in protecting both young children and older populations from preventable diseases has been one of the trend's most important drivers. The ability to access more information, including scientific research and educational campaigns, has given people and families the power to make well-informed vaccination decisions. Many people now regard vaccination as a critical component of public health because they are aware of the possible repercussions of diseases that can be prevented through vaccination. Government programs have also been essential in promoting vaccination use in Europe. Numerous European nations have put in place thorough immunization programs, providing kids and senior adults with a variety of vaccines for free or at a low cost. These measures have not only made vaccinations more accessible, but they have also highlighted how crucial timely immunization is. Some European governments have enacted legislative measures, such as vaccine requirements for specific groups or diseases, to promote vaccine coverage. When carefully planned and put into place, these requirements have been successful in reaching high vaccination rates.

On the basis of geography, the market is segmented into European countries like; Germany, United Kingdom (UK), France, Italy, Spain, and Russia. Among these, the Germany leads the market. Germany has a strong infrastructure for vaccine production, with state-of-the-art manufacturing facilities and research centers. This infrastructure ensures the quality and safety of vaccines produced within the country. Germany adheres to strict regulatory standards, with the Paul Ehrlich Institute overseeing vaccine quality control and safety. Public opinion on vaccinations in Germany is positive; as a result, the current national vaccination rate is around 93%. Recent years have seen a noteworthy rise in vaccine acceptability and awareness in the United Kingdom, which has had a positive impact on the nation's overall vaccine business. In France, the usage of vaccines has played a pivotal role in expanding and nurturing the growth of the vaccine market over the years. The country has a long-standing commitment to public health and an established tradition of vaccination, with mandatory vaccination programs dating back to the 19th century.

Depending on the pathogen (bacteria or virus) that is been targeted, different vaccines technologies are used to produce a vaccine. Therefore, the market is segmented on the basis of Technology; it includes Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, and Toxoid vaccines. In the European vaccine market the utilization of Conjugated vaccines holds the largest market share. In Europe, influenza occurs in regular annual epidemics in the winter season. It is estimated that up to 50 million people are infected with seasonal influenza viruses in the European Union (EU)/European Economic Area (EEA) each year. Therefore, the conjugate vaccines are best adapted to cure the disease. Measles is an acute viral infectious disease that can lead to significant morbidity and mortality in past around the globe. In European countries, measles is still one of the challenging health issues with evidence of re-emerging of new cases. The use of Live Attenuated Vaccines has dramatically reduced the incidence of measles in Europe. Poliomyelitis is a viral disease that affects the central nervous system. Historically, it has been a major cause of death, acute paralysis and lifelong disabilities. The polio vaccine is a critical and compulsory immunization for children worldwide. This polio vaccine is a Recombinant vaccine, and its usage has boosted the overall growth of the Europe vaccine market. Polio vaccination coverage in Europe is very high. In 2021, 96% of children in Europe received the recommended doses of the polio vaccine.

The market is segmented based on the Route of Administration of vaccine, which includes Intramuscular and Subcutaneous Administration, Oral Administration, and Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.) Each vaccine has a recommended administration route and site. This information is included in the manufacturer’s package insert for each vaccine. Most vaccines are administered through either intramuscular (IM) or subcutaneous (SC) routes because these methods offer distinct advantages in terms of immune response and safety. Thus this method holds the largest market size of near to 14 Billion in 2022. Intramuscular administration involves injecting the vaccine into a specific muscle, typically the deltoid muscle in the upper arm or the vastus lateralis muscle in the thigh. This method is preferred for certain vaccines because muscle tissue provides a robust environment for the vaccine to stimulate the immune system. The muscle tissue has a rich blood supply, allowing for efficient absorption and distribution of the vaccine antigens. Additionally, intramuscular injections generally produce a strong and long-lasting immune response, making them suitable for vaccines against diseases like measles, mumps, rubella, and hepatitis B. Subcutaneous injections are typically administered in the upper arm or thigh. Some vaccines given by this route include those for influenza, rabies, and the bacillus Calmette-Guérin (BCG) vaccine for tuberculosis prevention. Subcutaneous injections are generally well-tolerated and cause minimal discomfort. Oral administration of vaccines offers several distinct advantages, making it a valuable approach in immunization efforts. Unlike injections, which can be more invasive and require skilled healthcare personnel, oral vaccines are administered by mouth, often in the form of drops, tablets, or capsules. Examples of vaccines administered orally include the oral polio vaccine (OPV), which has been instrumental in nearly eradicating polio worldwide. Rotavirus vaccines, such as RotaTeq and Rotarix, are also administered orally and protect against severe diarrheal disease caused by rotavirus infection. Another example is the cholera vaccine, which can be given orally and provides protection against cholera, a waterborne disease. A promising and cutting-edge method of vaccine delivery is provided by microneedle patches. They may be able to deal with some of the issues that traditional needle-based vaccinations have, such as pain, needlestick injuries, and storage needs. Microneedle patches may become a more popular and practical way to administer a variety of vaccines as this technology develops.

On the basis of End-User’s, the market is segmented into Pediatric Vaccines and Adult Vaccines. The recommended schedule protects infants and children by providing protection early in life, before they come into contact with life-threatening diseases. Children receive vaccinations early because they are susceptible to diseases at a young age. Therefore, the usage of vaccines in Pediatrics’ holds the largest market share and the highest CAGR near to 7.75% for the year 2023-2028. The common compulsory vaccines for young children include Measles, Mumps, and Rubella (MMR) Vaccine, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Polio Vaccine, Haemophilus influenzae type b (Hib) Vaccine, Hepatitis B Vaccine, Pneumococcal Conjugate Vaccine (PCV), Varicella (Chickenpox) Vaccine, Hepatitis A Vaccine, Rotavirus Vaccine, and Meningococcal Vaccine. Vaccines for adults are important for several reasons, including the need to protect individual health and well-being, prevent the spread of infectious diseases, and maintain community immunity. Influenza (Flu) Vaccine, COVID-19 Vaccine, Tetanus, Diphtheria, and Pertussis (Tdap) Vaccine, Pneumococcal Vaccine, Shingles (Herpes Zoster) Vaccine, Hepatitis Vaccines, Meningococcal Vaccine, and Depending on travel destinations and activities, adults require vaccines such as typhoid, yellow fever, rabies, and others to protect against diseases prevalent in specific regions. The market is segmented based on the type of vaccines used to cure Diseases like Pneumococcal diseases, Cancer, Influenza, Rotavirus, Diphtheria, Pertussis, and Tetanus (DTP), Human Papilloma Virus (HPV), Shingles, Meningococcal diseases, Hepatitis, Varicella (Chicken Pox), Mumps, Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.). Diseases caused by Streptococcus pneumonia (the pneumococcus) are a major public health problem in European countries, which has contributed to the largest usage of Pneumococcal Vaccines. Along with this, the usage of vaccines to cure cancers in European countries has increased, especially the use of HBV (human papillomaviruses) vaccines have boosted the overall growth of the marker.

According to the Type of vaccine, the market is segmented into multivalent vaccine and monovalent vaccine. Multivalent vaccines, which are designed to protect against multiple diseases or strains of a pathogen in a single shot, have become increasingly prevalent and crucial in modern vaccination strategies. These vaccines offer several advantages in terms of convenience, cost-effectiveness, and enhanced immunization coverage. Multivalent vaccines reduce the number of separate shots a person needs to receive to be fully protected against multiple diseases. Therefore, the market of multivalent vaccines holds the largest market share in 2022. Examples of widely used multivalent vaccines include the MMR vaccine, which protects against measles, mumps, and rubella; the pentavalent vaccine, which guards against five different diseases, including diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b; and the quadrivalent influenza vaccine, which provides protection against four influenza virus strains. Monovalent vaccines are a category of vaccines designed to provide protection against a single specific disease or pathogen. Unlike multivalent vaccines, which target multiple diseases or strains in a single shot, monovalent vaccines are focused on immunizing individuals against a single infectious agent. These vaccines are essential for preventing a wide range of diseases, from common childhood illnesses to emerging infectious threats. An example of a monovalent vaccine is the hepatitis B vaccine. This vaccine is formulated to protect against hepatitis B virus (HBV) infection, which can lead to chronic liver disease, cirrhosis, and liver cancer. The monovalent nature of the hepatitis B vaccine ensures that individuals receive targeted protection against this specific virus.

Based on the distributional channel, Vaccines are indeed primarily available in hospitals and pharmacies, as these settings typically meet the necessary conditions for proper vaccine storage and administration. Vaccines are sensitive biological products that require strict temperature control to maintain their effectiveness. Hospitals and pharmacies are equipped with the appropriate refrigeration units and storage protocols to ensure that vaccines are kept at the recommended temperatures, usually between 2 to 8 degrees Celsius (35.6 to 46.4 degrees Fahrenheit), to prevent their degradation. Hospitals play a crucial role in providing vaccines, especially for routine immunization programs, as they have healthcare professionals who can administer vaccines safely and monitor for any adverse reactions. Hospital pharmacies hold the market share of more than 40%. Primary care clinics and healthcare facilities associated with hospitals are also common sites for vaccine administration. Pharmacies, on the other hand, offer convenience and accessibility to vaccines. Many retail pharmacies have dedicated vaccine storage units and trained pharmacists or nurses who can administer vaccines. This accessibility makes it easier for individuals to receive vaccinations without needing to visit a healthcare facility or make a doctor's appointment. In some cases, vaccines may also be available in specialized immunization clinics or public health centers, especially during vaccination campaigns or in response to specific outbreaks.

Companies covered in the report:

Merck & Co., Inc, BioNTech SE, Bavarian Nordic, GlaxoSmithKline PLC, Bharat Biotech International Limited, CSL, Charles River Laboratories, Creative, Biogene, Daiichi Sankto Company Ltd, Emergent BioSolutions Inc., Sanofi S.A, AstraZeneca plc, Novavax, Oxford Biomedica, Pfizer Inc, Takeda Pharmaceutical Company Limited.

Considered in this report:

• Geography: Europe
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Europe Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Countries covered in the report:

• Germany
• United Kingdom
• France
• Spain
• Italy
• Russia

By Technology:

• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:

• Paediatric Vaccines
• Adult Vaccines

By End-User:

• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:

• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.